VA
VTVT icon

Verdad Advisers’s vTv Therapeutics VTVT Stock Holding History

Verdad Advisers’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$339K Buy
+8,996
New +$312K 0.32% 108

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verdad Advisers's VTVT Position: Q2 2026 in Review

Verdad Advisers opened a new position in vTv Therapeutics (VTVT) in Q2 2026: 8,996 shares worth $339K. The stake represents 0.32% of the portfolio and ranks #108 among its holdings.

45 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

  • Verdad Advisers held 8,996 shares of vTv Therapeutics worth $339K as of Q2 2026.
  • vTv Therapeutics was a new Verdad Advisers position in Q2 2026.
  • vTv Therapeutics made up 0.32% of Verdad Advisers's portfolio in Q2 2026, its #108 holding.
  • 45 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.